Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases

Abstract Background Metaplastic breast cancer (MpBC) is an aggressive subtype of breast carcinoma that is often resistant to conventional chemotherapy. Therefore, novel treatment strategies are urgently needed. Immune check point inhibitors have shown activity in programmed death-ligand 1 (PD-L1) –...

Full description

Bibliographic Details
Main Authors: S. Voutilainen, P. Heikkilä, J. Bartkova, H. Nevanlinna, C. Blomqvist, J. Bartek, J. Mattson
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-022-10408-7